OR-812: Pioneering Treatment for Inflammatory Bowel Disease (IBD)

Inflammatory Bowel Disease (IBD) presents a significant treatment challenge for patients and their healthcare professionals, with long-term remission rates below 50% for existing drugs. This underscores a critical need for novel therapeutic approaches in the clinical landscape.

At the heart of IBD’s complex pathology is the role of retinoic acid receptor-α (RARα) in regulating gut inflammation.

Orphagen’s OR-812 emerges as a groundbreaking, orally active RARα antagonist. This first-in-class molecule prevents the induction of key gut-homing receptors, CCR9 and α4β7, during T cell activation or inflammation. This targeted mechanism offers a promising new direction in IBD treatment.

As a major market in autoimmune diseases, IBD treatment demands innovative solutions. OR-812, as a novel oral retinoid antagonist, has the potential to broadly benefit patients, addressing the substantial gap in effective long-term remission.

Orphagen is a pioneer in this transformative approach for Crohn’s and ulcerative colitis patients.